title: Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia.
abstract: OBJECTIVE
  To analyse the efficacy of low-dose rosuvastatin for treating hypo high-density lipoprotein (HDL) cholesterolaemia in patients with type 2 diabetes and dyslipidaemia.
  
  
  METHODS
  Patients with HDL-cholesterol (C) < 40 mg/dl and triglycerides (TG) < 400 mg/dl who were receiving treatment with lipid-lowering drugs other than rosuvastatin (or previously untreated with lipid-lowering drugs) and with low-density lipoprotein [LDL]-C ≥ 120 mg/dl were included. Patients were treated with 2.5 or 5 mg rosuvastatin orally, once daily, to achieve the target LDL-C level specified in Japanese guidelines. Changes in total cholesterol, HDL-C, TG, LDL-C, LDL-C/HDL-C and non-HDL-C at 3 and 6 months were prospectively analysed. Safety was evaluated by examining changes in hepatorenal function, glucose metabolism and creatine kinase.
  
  
  RESULTS
  Out of 49 patients, all lipid parameters other than TG were significantly improved at 3 and 6 months. At 3 months, 83.3% of patients had achieved the target LDL-C level. Among nonlipid parameters, no changes were observed except for estimated glomerular filtration rate, which was improved by + 5.2% and + 9.6% at 3 and 6 months, respectively.
  
  
  CONCLUSIONS
  Low-dose rosuvastatin was effective in improving hypo-HDL cholesterolaemia and may have renoprotective effects.
authors.affiliation: Division of Metabolism and Endocrinology, Department of Internal Medicine, St Marianna University School of Medicine Yokohama City Seibu Hospital, Yokohama, Japan.
authors.forename: Takuyuki
authors.initials: T
authors.lastname: Katabami
authors.forename: Mariko
authors.initials: M
authors.lastname: Murakami
authors.forename: Suzuko
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Tomoya
authors.initials: T
authors.lastname: Matsui
authors.forename: Makoto
authors.initials: M
authors.lastname: Ujihara
authors.forename: Sachiko
authors.initials: S
authors.lastname: Takagi
authors.forename: Mariko
authors.initials: M
authors.lastname: Higa
authors.forename: Takamasa
authors.initials: T
authors.lastname: Ichijo
authors.forename: Akio
authors.initials: A
authors.lastname: Ohta
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Tanaka
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D008076:Cholesterol, HDL / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood; D003402:Creatine Kinase / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D050171:Dyslipidemias / Q000188:drug therapy*; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D005947:Glucose / Q000378:metabolism; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011743:Pyrimidines / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood; D055815:Young Adult
chemical_list: D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; D011743:Pyrimidines; D013449:Sulfonamides; D014280:Triglycerides; D000068718:Rosuvastatin Calcium; D003402:Creatine Kinase; D005947:Glucose
keywords: Type 2 diabetes mellitus; estimated glomerular filtration rate; hypo high-density lipoprotein cholesterolaemia; low-density lipoprotein cholesterol; rosuvastatin; triglycerides